Stage 3 Kidney Disease: Learn More About It

Reaching stage 3 of chronic kidney disease (CKD) means your kidneys are filtering less efficiently than normal, and the risk of complications starts to rise. The good news is that many causes are manageable, and careful follow-up can slow progression for many people. Stage 3 is also when routine lab trends, medication choices, and lifestyle factors tend to matter more than any single test result.

Understanding stage 3 kidney disease: causes and care

CKD is usually the result of long-term damage to the kidneys rather than a sudden event. Worldwide, the most common contributors include diabetes and high blood pressure, which can gradually injure the kidney’s filtering units. Other causes can include chronic inflammation of the kidneys, inherited conditions (such as polycystic kidney disease), repeated kidney infections, urinary tract obstruction (for example from prostate enlargement or stones), and medication-related injury (notably long-term or high-dose use of certain pain relievers).

Management in stage 3 typically focuses on addressing the cause, reducing strain on the kidneys, and preventing complications. Depending on the individual, clinicians may prioritize blood pressure control, blood sugar optimization, reviewing medications for kidney safety, and reducing cardiovascular risk. Some people are advised to limit sodium and to adjust protein intake to a level appropriate for their health status and nutrition needs. Because CKD affects how the body handles minerals and fluids, individualized guidance can be especially important rather than broad rules.

What stage 3 kidney disease means: staging and risks

CKD staging is primarily based on estimated glomerular filtration rate (eGFR), a calculation that reflects filtering capacity using blood creatinine (and sometimes other markers) along with age and other factors. Stage 3 generally corresponds to an eGFR of about 30–59 mL/min/1.73 m² and is often split into:

• Stage 3a: eGFR about 45–59
• Stage 3b: eGFR about 30–44

Risk is not determined by eGFR alone. A second major piece is albumin (protein) in the urine, which can signal ongoing kidney injury. Higher urine albumin levels generally correlate with higher risk of progression and cardiovascular disease.

In stage 3, potential complications become more likely, including anemia (low red blood cell count), bone and mineral disorders (involving calcium, phosphate, and parathyroid hormone), metabolic acidosis (low bicarbonate), fluid retention, and rising potassium. People with CKD also face increased cardiovascular risk, so clinicians often pay close attention to blood pressure, lipid levels, and smoking status, alongside kidney-specific measures.

Recognizing symptoms and when to seek medical help

Stage 3 CKD can be silent. When symptoms occur, they may be nonspecific and easy to attribute to other causes. Possible symptoms include fatigue, reduced exercise tolerance, swelling in the ankles or around the eyes, changes in urination (frequency, foamy urine, or nighttime urination), itchy skin, muscle cramps, nausea, or trouble concentrating. These can also reflect anemia, fluid shifts, or electrolyte changes that sometimes develop as kidney function declines.

Seek prompt medical attention for warning signs that may indicate a complication or another urgent problem, such as shortness of breath, chest pain, fainting, confusion, severe weakness, persistent vomiting, significantly reduced urine output, or rapidly worsening swelling. Even without dramatic symptoms, contacting a clinician is important if home blood pressure readings trend upward, if new medications are started (including over-the-counter pain relievers or supplements), or if an intercurrent illness leads to dehydration, since these can affect kidney function.

Diagnostic tests and monitoring: eGFR, urine, imaging

Diagnosis and follow-up typically rely on repeated measurements rather than a single result. eGFR is used to stage CKD and to track trends over time. A urine albumin-to-creatinine ratio (ACR) or protein testing helps quantify protein loss, which is a key prognostic factor and a treatment target in many cases. Basic blood work commonly includes electrolytes (especially potassium), bicarbonate, blood urea nitrogen (BUN), and sometimes calcium, phosphate, parathyroid hormone, and vitamin D markers depending on risk and stage.

Imaging, most often kidney ultrasound, may be used to evaluate kidney size and structure, identify obstruction, assess cysts, or look for scarring. In selected situations, clinicians may recommend additional tests such as autoimmune labs, genetic evaluation, or a kidney biopsy, particularly when the cause is unclear or the pattern of disease is atypical.

Monitoring frequency varies by stage, urine albumin level, comorbidities, and the stability of prior results. A stable stage 3a case with low albumin may need less frequent testing than stage 3b with significant albuminuria, rising potassium, or medication changes that affect kidney handling of electrolytes.

Everyday management: blood pressure, diet, and medications

Day-to-day management often centers on reducing further injury and preventing complications. Blood pressure targets and medication selection are individualized; in many patients, clinicians use medications that protect kidney function in the presence of albuminuria, such as ACE inhibitors or ARBs, while monitoring potassium and creatinine after initiation or dose changes. For people with type 2 diabetes and CKD, certain glucose-lowering therapies may be considered that also have kidney and cardiovascular benefits, depending on eligibility and safety considerations.

Diet and lifestyle measures are usually practical rather than extreme: moderating sodium intake to help control blood pressure and fluid retention, maintaining an appropriate calorie and protein intake to support muscle mass, and managing diabetes with consistent eating patterns. Because potassium and phosphate can become problematic in some people as CKD advances, food choices may need adjustment based on lab results rather than generic avoidance lists. Regular physical activity (adapted to ability), sleep, and smoking cessation can support cardiovascular health, which is closely linked to kidney outcomes.

This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalized guidance and treatment.

Stage 3 CKD is defined by moderate reduction in kidney function and is best understood through trends in eGFR, urine albumin, and overall health risks rather than symptoms alone. With structured monitoring and individualized management of blood pressure, diabetes, medications, and nutrition, many people can reduce complication risk and slow progression while maintaining a good quality of life.